Weimi Bio-Tech

About Weimi Bio-Tech

Guangzhou Weimi Bio-Tech Co., Ltd., established in September 2013, is a national high-tech enterprise focused on the in-vitro diagnostics (IVD) sector, integrating research and development, manufacturing, and sales from its base in Guangzhou's Science City. The company was founded by Wang Tao, who brings over two decades of experience in clinical medicine, operations, and management to his role as chairman. His leadership has been central to the company's strategic direction and growth.

Weimi Bio-Tech operates as a developer and provider of comprehensive diagnostic solutions for medical laboratories. Its business model revolves around the R&D, production, and distribution of IVD test kits and related instruments. The company has established a broad sales network across China, serving hospitals and diagnostic centers with both products and technical support. Revenue is generated through the sale of these diagnostic products. Financially, the company has shown significant progress, securing an A-round in 2018, an A+ round in 2019 from investors including Jinhe Capital and Mefund Capital, and a substantial Series B of over 100 million RMB in 2021 led by CICC Capital.

The company's product portfolio is extensive, covering a wide range of disease diagnostics including cardio-cerebrovascular, inflammation, prenatal, cancer, diabetes, and kidney diseases. Weimi Bio-Tech has developed multiple technology platforms, such as time-resolved immunofluorescence chromatography, chemiluminescence, flow fluorescence, and molecular diagnostics. This multi-platform strategy allows it to offer a comprehensive suite of products, from rapid point-of-care tests (POCT) to more complex laboratory assays, addressing needs across various hospital departments. A key achievement is its recognition as the Guangdong Provincial Engineering Center for Precision Diagnosis of Neuroimmune Diseases, highlighting its capabilities in specialized diagnostic fields.